CISYS LifeSciences isn’t attending EULAR this year, but we support rheumatology research with tools for eligibility, adjudication, collaboration, and coding.
EULAR is an exciting opportunity to share innovations and accelerate progress in rheumatology. Though we won’t be shaking hands at the conference this year, CISYS LifeSciences stands ready to support your trials with the tools that matter most—purpose-built, compliant, and user-friendly solutions for clinical teams.
For years, CISYS has worked closely with both large global CROs and emerging biotech sponsors in the autoimmune and musculoskeletal space. We’ve supported teams working on rheumatoid arthritis, lupus, psoriatic arthritis, and other complex conditions—giving us direct insight into the hurdles they face. From inconsistent site processes and delayed submissions to adjudication bottlenecks and coding backlogs, we’ve seen the spectrum of operational pain points up close. That experience is reflected in the Sequence Platform: every product was shaped in response to real-world challenges observed across hundreds of studies.
Here’s how the CISYS Sequence Platform can support your rheumatology study from start to finish:
WebPatient: Patient Eligibility, Simplified
- Challenge: Eligibility criteria in rheumatology trials can be complex—spanning symptoms, lab results, imaging, and clinician assessments.
- Solution: WebPatient is a centralized, protocol-specific patient eligibility platform that streamlines the review process across sites. With intelligent forms, configurable workflows, and transparent submission tracking, it empowers your team to make fast, protocol-compliant enrollment decisions without drowning in email or spreadsheets.
WebEAS: Confident Adjudication of Complex Endpoints
- Challenge: Events like joint deterioration, remission, or flare-ups require precise, blinded adjudication—often with diverse documentation inputs.
- Solution: WebEAS supports blinded adjudication across specialties, with features like document review, DICOM imaging, customizable workflows, and multi-vote logic. Whether you’re adjudicating autoimmune flares or imaging-based endpoints, WebEAS ensures decisions are timely, traceable, and regulatory-ready.
WebFXP: Sponsor-Site Communication Without the Chaos
- Challenge: Sites are overwhelmed with email chains, fragmented submissions, and inconsistent instructions across trials.
- Solution: WebFXP is your secure sponsor-site communications hub. Upload, manage, and track documents, images, and forms in a centralized portal—eliminating delays and ensuring version control. For complex, multi-site rheumatology studies, this means faster responses, clearer visibility, and less friction at every stage.
WebCode: Medical Coding That Keeps Pace With Your Data
- Challenge: Manual coding of medications and adverse events consumes valuable time and introduces risk—especially when done at scale.
- Solution: WebCode automates WHO Drug and MedDRA coding with industry-standard accuracy. Use your own synonym lists, configure workflows, and batch-process large datasets—all while maintaining regulatory compliance. From coding steroid therapies to AE terms across autoimmune studies, WebCode cuts the time from data entry to clean dataset.
Why It All Works: The CISYS Sequence Platform
The CISYS Sequence Platform unites these products into a single, harmonized environment. Whether you’re a sponsor, CRO, or site team, you get:
- Role-based access controls
- End-to-end audit trails
- Scalable integration with your existing systems
- Built-in flexibility for global, multi-center studies
Let’s Talk—Even If It’s Not in the Exhibit Hall
Even though we’re not at EULAR this year, we’re just a click away. If you’re interested in seeing how the Sequence Platform can improve your clinical operations—or just want to explore one of our products in more depth—reach out. We’d love to meet you.
To the rheumatology research community: we’re here, we’re listening, and we’re building tools that help you move faster, smarter, and with confidence.